158 related articles for article (PubMed ID: 2963927)
21. Effects of nicorandil on the conductive coronary artery of the dog.
Imai S; Nakazawa M; Takeda K; Nakagawa Y; Katano Y; Tsukada T; Nabata H; Ushijima T
J Cardiovasc Pharmacol; 1987; 10 Suppl 8():S10-6. PubMed ID: 2447415
[TBL] [Abstract][Full Text] [Related]
22. Coronary dilating effects of intracoronary nicorandil. Comparison with isosorbide dinitrate.
Ejima J; Kaneda K; Moriyama H; Ohmura I; Maruyama T; Kaji Y; Tsuda Y; Kanaya S; Fujino T; Niho Y
Jpn Heart J; 1995 Nov; 36(6):699-707. PubMed ID: 8627976
[TBL] [Abstract][Full Text] [Related]
23. Acute and subacute effects of nicorandil and isosorbide dinitrate on vessel wall properties of large arteries and hemodynamics in healthy volunteers.
Kool MJ; Spek JJ; Struyker Boudier HA; Hoeks AP; Reneman RS; van Herwaarden RH; Van Bortel LM
Cardiovasc Drugs Ther; 1995 Apr; 9(2):331-7. PubMed ID: 7662600
[TBL] [Abstract][Full Text] [Related]
24. Nicorandil: differential contribution of K+ channel opening and guanylate cyclase stimulation to its vasorelaxant effects on various endothelin-1-contracted arterial preparations. Comparison to aprikalim (RP 52891) and nitroglycerin.
Borg C; Mondot S; Mestre M; Cavero I
J Pharmacol Exp Ther; 1991 Nov; 259(2):526-34. PubMed ID: 1682478
[TBL] [Abstract][Full Text] [Related]
25. Interactions of nitrovasodilators, atrial natriuretic peptide and endothelium-derived nitric oxide.
Murohara T; Kugiyama K; Yasue H
J Vasc Res; 1996; 33(1):78-85. PubMed ID: 8603131
[TBL] [Abstract][Full Text] [Related]
26. Dilator effects of nicorandil on isolated perfused coronary arteries of humans.
Sakaino N; Araki H; Nishi K
Arch Int Pharmacodyn Ther; 1990; 306():100-5. PubMed ID: 2150166
[TBL] [Abstract][Full Text] [Related]
27. ITF 296, a new endothelium-independent vasodilator: comparison with nitroglycerin and isosorbide dinitrate.
Ghaleh B; Dubois-Randé JL; Hittinger L; Berdeaux A; Giudicelli JF
J Cardiovasc Pharmacol; 1995; 26 Suppl 4():S6-12. PubMed ID: 8839220
[TBL] [Abstract][Full Text] [Related]
28. Mechanism of action of KRN2391 in canine coronary vascular bed.
Fukata Y; Kaneta S; Okada Y; Yokoyama T; Jinno Y; Fukushima H; Ogawa N
Jpn J Pharmacol; 1993 Nov; 63(3):305-11. PubMed ID: 8107323
[TBL] [Abstract][Full Text] [Related]
29. Studies of vascular tolerance to nitroglycerin: effects of N-acetylcysteine, NG-monomethyl L-arginine, and endothelin-1.
Lawson DL; Haught WH; Mehta P; Mehta JL
J Cardiovasc Pharmacol; 1996 Sep; 28(3):418-24. PubMed ID: 8877589
[TBL] [Abstract][Full Text] [Related]
30. Specificity of different organic nitrates to elicit NO formation in rabbit vascular tissues and organs in vivo.
Mülsch A; Bara A; Mordvintcev P; Vanin A; Busse R
Br J Pharmacol; 1995 Nov; 116(6):2743-9. PubMed ID: 8590999
[TBL] [Abstract][Full Text] [Related]
31. Salutary action of nicorandil, a new antianginal drug, on myocardial metabolism during ischemia and on postischemic function in a canine preparation of brief, repetitive coronary artery occlusions: comparison with isosorbide dinitrate.
Pieper GM; Gross GJ
Circulation; 1987 Oct; 76(4):916-28. PubMed ID: 2958176
[TBL] [Abstract][Full Text] [Related]
32. Dissimilarity in the mechanisms of action of KRN2391, nicorandil and cromakalim in canine renal artery.
Kasai H; Fukata Y; Harada K; Fukushima H; Ogawa N
J Pharm Pharmacol; 1993 Mar; 45(3):222-4. PubMed ID: 8097782
[TBL] [Abstract][Full Text] [Related]
33. Effects of N-acetylcysteine on nitroglycerin-induced relaxation and protein phosphorylation of porcine coronary arteries.
Tate Y; Kawasaki K; Ishibashi S; Ikeda U; Shimada K
Heart Vessels; 1998; 13(6):263-8. PubMed ID: 10651168
[TBL] [Abstract][Full Text] [Related]
34. Comparisons of the effects of nicorandil, pinacidil, nicardipine and nitroglycerin on coronary vessels in the conscious dog: role of the endothelium.
Ghaleh B; Dubois-Randé JL; Hittinger L; Giudicelli JF; Berdeaux A
Br J Pharmacol; 1995 Jan; 114(2):496-502. PubMed ID: 7881748
[TBL] [Abstract][Full Text] [Related]
35. Nicorandil-induced vasorelaxation: functional evidence for K+ channel-dependent and cyclic GMP-dependent components in a single vascular preparation.
Meisheri KD; Cipkus-Dubray LA; Hosner JM; Khan SA
J Cardiovasc Pharmacol; 1991 Jun; 17(6):903-12. PubMed ID: 1714013
[TBL] [Abstract][Full Text] [Related]
36. Potentiating effect of nicorandil, an antianginal agent, on relaxation induced by isoproterenol in isolated rat aorta: involvement of cyclic GMP-inhibitable cyclic AMP phosphodiesterase.
Satake N; Zhou Q; Morikawa M; Inoue M; Shibata S
J Cardiovasc Pharmacol; 1995 Mar; 25(3):489-94. PubMed ID: 7769818
[TBL] [Abstract][Full Text] [Related]
37. The inhibitory mechanisms of nicorandil in isolated rat urinary bladder and femoral artery.
Zhou Q; Satake N; Shibata S
Eur J Pharmacol; 1995 Jan; 273(1-2):153-9. PubMed ID: 7737309
[TBL] [Abstract][Full Text] [Related]
38. Analysis of relaxation and repolarization mechanisms of nicorandil in rat mesenteric artery.
Fujiwara T; Angus JA
Br J Pharmacol; 1996 Dec; 119(8):1549-56. PubMed ID: 8982500
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of nicorandil in the preservation of myocardium stressed by transient ischemia and its influence on cardiac metabolism during coronary artery occlusion with subsequent reperfusion: a comparison with isosorbide dinitrate.
Korb H; Hoeft A; Hunneman DH; Schraeder R; Wolpers HG; Hellige G
Naunyn Schmiedebergs Arch Pharmacol; 1985 Jun; 329(4):440-6. PubMed ID: 3162106
[TBL] [Abstract][Full Text] [Related]
40. Mechanism of relaxant effects of nicorandil on the dog coronary artery.
Imai S; Ushijima T; Nakazawa M; Nabata H; Sakai K
Arch Int Pharmacodyn Ther; 1983 Oct; 265(2):274-82. PubMed ID: 6228201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
